NewsCase StudiesEvents

GlaxoSmithKline investing in Greece

Also in the news...

Growth Gateway: Laos sustainability opportunities

Laos could unlock up to £270 million in GDP and create 55,000 jobs by 2030 through targeted climate investments in agriculture, energy and forestry.

UK Trade Envoy in Cambodia to boost trade and investment   

UK Trade Envoy Matt Western MP visits Cambodia to strengthen trade and investment ties and support Cambodia’s sustainable economic development.

Who is subject to financial sanctions in the UK?

A guide to the current consolidated list of asset freeze targets, and a list of persons named in relation to financial and investment restrictions under the Russia regulations

Homes for Ukraine visa sponsorship scheme: privacy notice

Homes for Ukraine visa sponsorship scheme: How we use personal data.

Check duties and customs procedures for exporting goods

Find information about how to move goods from the UK to the rest of the world.

GlaxoSmithKline investing in Greece

Back to News

The leading UK pharmaceutical company, Glaxo Smithkline (GSK) announced new €2.2 million investment in Greece, at the British Residence.

This investment will enable secondary packaging for 4 over-the-counter products. This will take place at FAMAR’s facilities, in the context of a long-term cooperation between the two companies. Production is expected to begin before the end of the year and will reinforce the exporting capacity of GSK Greece, as 98% of the new production will be exported to 32 countries.

The Minister for Development, Costis Hatzidakis, opened the event alongside the host, the British Ambassador, John Kittmer, who said:

I am delighted that GSK, a great British company, has decided to increase its investment in Greece. This decision shows the importance of foreign direct investment to Greece’s future and the importance of Greece’s efforts to improve the business environment.

gov.uk

You are not logged in!

Please login or register to ask our experts a question.

Login now or register.